Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

PLoS Pathogens

Volumn 11, Issue 2, 2015, Pages

  Hancock, Gemma ^a,b   Yang, Hongbing ^a,b   Yorke, Elisabeth ^c   Wainwright, Emma ^d   Bourne, Victoria ^a   Frisbee, Alyse ^e   Payne, Tamika L ^e   Berrong, Mark ^e   Ferrari, Guido ^e   Chopera, Denis ^f   Hanke, Tomas ^a   Mothe, Beatriz ^g   Brander, Christian ^g,h   McElrath, M Juliana ⁱ   McMichael, Andrew ^a   Goonetilleke, Nilu ^j   Tomaras, Georgia D ^e   Frahm, Nicole ⁱ   Dorrell, Lucy ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

ⁱ USA   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; EPITOPE; FLUORESCEIN ISOTHIOCYANATE; GAG PROTEIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HVTN 502; HVTN 503; INTERLEUKIN 2; NEF PROTEIN; PLACEBO; POL PROTEIN; PROTEOME; UNCLASSIFIED DRUG; VIF PROTEIN;

ADULT; ALLELE; ANTIVIRAL ACTIVITY; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNE RESPONSE; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T CELL CULTURE; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINATION REACTION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; CLASSIFICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; MALE; MIDDLE AGED; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 84924371170     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004658     Document Type: Article

References (66)

1. Buchbinder SP, Mehrotra D V, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881–1893. doi: 10.1016/S0140-6736(08)61591-3 19012954
2. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894–1905. doi: 10.1016/S0140-6736(08)61592-5 19012957
3. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, et al. (2013) Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med 369: 2083–2092. doi: 10.1056/NEJMoa1310566 24099601
4. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al. (2009) Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 83: 6508–6521. doi: 10.1128/JVI.00272-09 19403685
5. Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, et al. (2011) Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog 7: e1002002. doi: 10.1371/journal.ppat.1002002 21383976
6. Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, et al. (2013) Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. J Infect Dis 208: 1231–1239. doi: 10.1093/infdis/jit322 23878319
7. Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, et al. (2011) Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 6: e20479. doi: 10.1371/journal.pone.0020479 21695251
8. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, et al. (2014) Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22: 464–475. doi: 10.1038/mt.2013.248 24166483
9. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, et al. (2011) Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11: 507–515. doi: 10.1016/s1473–3099(11)70098-6 21570355
10. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46–53. 17173051
11. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. J Virol 80: 3122–3125. 16501126
12. Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, et al. (2013) HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. PLoS Pathog 9: e1003404. doi: 10.1371/journal.ppat.1003404 23818843
13. Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, et al. (2013) Extreme Genetic Fragility of the HIV-1 Capsid. PLoS Pathog 9: e1003461. doi: 10.1371/journal.ppat.1003461 23818857
14. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208. doi: 10.1186/1479-5876-9-208 22152067
15. Rolland M, Nickle DC, Mullins JI, (2007) HIV-1 Group M Conserved Elements Vaccine. PLoS Pathog 3: e157. 18052528
16. Yang H, Wu H, Hancock G, Clutton G, Sande N, et al. (2012) Antiviral Inhibitory Capacity of CD8+ T cells Predicts the Rate of CD4+ T-Cell Decline in HIV-1 Infection. J Infect Dis 206: 552–561. doi: 10.1093/infdis/jis379 22711904
17. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776–6781. 17428922
18. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, et al. (2010) Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 84: 5540–5549. doi: 10.1128/JVI.02031-09 20335261
19. Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, et al. (2010) Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8+ T Cells. J Virol 84: 10543–10557. doi: 10.1128/JVI.00793-10 20686036
20. Buckheit RW, Salgado M, Silciano RF, Blankson JN, (2012) Inhibitory Potential of Subpopulations of CD8+ T Cells in HIV-1-Infected Elite Suppressors. J Virol 86: 13679–13688. doi: 10.1128/jvi.02439-12 23055552
21. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, et al. (2012) Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. J Virol 86: 6835–6846. doi: 10.1128/JVI.00437-12 22514337
22. Tomaras GD, Lacey SF, McDanal CB, Ferrari G, Weinhold KJ, et al. (2000) CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc Natl Acad Sci 97: 3503–3508. doi: 10.1073/pnas.97.7.3503 10725407
23. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, et al. (2010) Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84: 4998–5006. doi: 10.1128/JVI.00138-10 20200250
24. Lécuroux C, Girault I, Chéret A, Versmisse P, Nembot G, et al. (2013) CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection. PLoS One 8: e59767. doi: 10.1371/journal.pone.0059767 23555774
25. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, et al. (2008) Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5: e100. doi: 10.1371/journal.pmed.0050100 18462013
26. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, et al. (2010) Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 201: 720–729. doi: 10.1086/650492 20132004
27. Rolland M, Manocheewa S, Swain JV, Lanxon-Cookson EC, Kim M, et al. (2013) HIV-1 Conserved-Element Vaccines: Relationship between Sequence Conservation and Replicative Capacity. J Virol 87: 5461–5467. doi: 10.1128/JVI.03033-12 23468488
28. Kulkarni V, Rosati M, Valentin A, Ganneru B, Singh AK, et al. (2013) HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice. PLoS One 8: e60245. doi: 10.1371/journal.pone.0060245 23555935
29. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, et al. (2012) CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 7: e29717. doi: 10.1371/journal.pone.0029717 22238642
30. Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, et al. (2008) Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. J Virol 82: 9216–9227. doi: 10.1128/JVI.01041-08 18614631
31. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition. J Virol 83: 2743–2755. doi: 10.1128/JVI.02265-08 19116253
32. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. (2009) Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells. J Virol 83: 7641–7648. doi: 10.1128/JVI.00182-09 19458000
33. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, et al. (2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893–6904. doi: http://dx.doi.org/10.1016/j.vaccine.2006.06.009 16890329
34. Dorrell L, Yang H, Ondondo B, Dong T, de Gleria K, et al. (2006) Expansion and diversification of virus-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara / HIV-1 gag vaccine. J Virol 80: 4705–4716. 16641264
35. Hanke T, McMichael AJ, (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951–955. 10973301
36. Llano A, Williams A, Overa A, Silva-Arrieta S, Brander C, Yusim K, Korber B, Brander C, Barouch D, de Boer RJ, (2013) HIV Molecular Immunology 2013. et al., editors Los Alamos National Laboratory, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, New Mexico. doi: 10.1016/j.jfo.2013.06.003 25632406
37. Korber BT, Letvin NL, Haynes BF, (2009) T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces. J Virol 83: 8300–8314. doi: 10.1128/JVI.00114-09 19439471
38. Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319–323. doi: 10.1038/nm.2089 20173752
39. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2: e984. doi: 10.1371/annotation/fca26a4f-42c1-4772-a19e-aa9d96c4eeb2 17912361
40. Kopycinski J, Hayes P, Ashraf A, Cheeseman H, Lala F, et al. (2014) Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS One 9: e90378. doi: 10.1371/journal.pone.0090378 24609066
41. Koup RA, Safrit JT, Cao Y, Andrews C, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650–4655. 8207839
42. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of Viremia in Simian Immunodeficiency Virus Infection by CD8+ Lymphocytes. Science (80-) 283: 857–860.
43. Goonetilleke N, Liu MKP, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253–1272. doi: 10.1084/jem.20090365 19487423
44. Shapiro SZ, (2014) Clinical Development of Candidate HIV Vaccines: Different Problems for Different Vaccines. AIDS Res Hum Retroviruses 30: 325–329. doi: 10.1089/aid.2013.0114 24168166
45. Manocheewa S, Swain JV, Lanxon-Cookson E, Rolland M, Mullins JI, (2013) Fitness Costs of Mutations at the HIV-1 Capsid Hexamerization Interface. PLoS One 8: e66065. doi: 10.1371/journal.pone.0066065 23785468
46. Streeck H, Lu R, Beckwith N, Milazzo M, Liu M, et al. (2014) Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome. J Virol 88: 12793–12801. doi: 10.1128/JVI.02016-14 25165102
47. Pereyra F, Heckerman D, Carlson JM, Kadie C, Soghoian DZ, et al. (2014) HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes. J Virol 88: 12937–12948. doi: 10.1128/JVI.01004-14 25165115
48. Ganusov V V, Goonetilleke N, Liu MKP, Ferrari G, Shaw GM, et al. (2011) Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. J Virol 85: 10518–10528. doi: 10.1128/JVI.00655-11 21835793
49. Boutwell CL, Carlson JM, Lin T-H, Seese A, Power KA, et al. (2013) Frequent and Variable Cytotoxic-T-Lymphocyte Escape-Associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins. J Virol 87: 3952–3965. doi: 10.1128/JVI.03233-12 23365420
50. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781–4789. 16467198
51. Riou C, Burgers WA, Mlisana K, Koup RA, Roederer M, et al. (2014) Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8+ T Cell Responses on HIV Set Point. J Virol 88: 1819–1824. doi: 10.1128/JVI.02968-13 24227857
52. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, et al. (2012) Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys. J Virol 86: 11434–11440. doi: 10.1128/JVI.01779-12 22896617
53. Kulkarni V, Valentin A, Rosati M, Alicea C, Singh AK, et al. (2014) Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques. PLoS One 9: e86254. doi: 10.1371/journal.pone.0086254 24465991
54. Valkenburg SA, Gras S, Guillonneau C, Hatton LA, Bird NA, et al. (2013) Preemptive priming readily overcomes structure-based mechanisms of virus escape. Proc Natl Acad Sci 110: 5570–5575. doi: 10.1073/pnas.1302935110 23493558
55. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature: Epub ahead of print.
56. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, et al. (2013) Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (80-) 340: 1237874. doi: 10.1126/science.1237874 23704576
57. Hansen SG, Piatak M, Jr.Ventura AB, Hughes CM, Gilbride RM, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502: 100–104. doi: 10.1038/nature12519 24025770
58. Liu MKP, Hawkins N, Ritchie AJ, Ganusov V V, Whale V, et al. (2013) Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 123: 380–393. doi: 10.1172/JCI65330 23221345
59. Fellay J, Shianna K V, Ge D, Colombo S, Ledergerber B, et al. (2007) A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science (80-) 317: 944–947.
60. Yang H, Dong T, Turnbull E, Ranasinghe S, Ondondo B, et al. (2007) Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy. J Immunol 179: 597–606. 17579081
61. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 17: 366–371. doi: 10.1038/nm.2316 21358627
62. De Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinforma 21: 3797–3800. doi: 10.1093/bioinformatics/bti607.
63. Alcantara LCJ, Cassol S, Libin P, Deforche K, Pybus OG, et al. (2009) A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 37: W634–W642. doi: 10.1093/nar/gkp455 19483099
64. Koup RA, Ho DD, Poli G, Fauci AS, (2001) Isolation and quantitation of HIV in peripheral blood. Curr Protoc Immunol 5: 2.1–2.11. doi: 10.1002/0471142735.im1202s05.
65. Yang H, Yorke E, Hancock G, Clutton G, Sande N, et al. (2013) Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. J Immunol Methods 391: 174–178. doi: 10.1016/j.jim.2013.03.001 23500782
66. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39–54. doi: http://dx.doi.org/10.1016/j.jim.2007.03.002 17451739